2
LipoGeneTM
Liposome Transfection ReagentProtocol
Package Contents: 1 vial
Storage
LipoGene can be stored at 4°C. Avoid repeated freezing and thawing. The expiry date is specified on the product
label.
DESCRIPTION
LipoGene Liposome transfection reagent is highly potent cationic lipofection reagent that has been shown to
effectively transfect plasmids or siRNA, as well as nucleic acid-protein complexes, into cultured adherent and
suspension cell lines. Researchers use LipoGene Reagent for siRNA- and shRNA-based gene knockdown
experiments, as well as for gene expression studies.
ADVANTAGES
1. Superior performance for co-transfection of siRNA and plasmid DNA.
2. Efficient in the presence of serum, which releases the need to change media following transfection.
LipoGeneTM
Transfection Reagent
Catalog No. Package Price Quantity/Unit Form Sipping and Storage Guidelines
R-LG01 0.5 ml 150
1 vial. Liquid.
Shipped at 4°C, stored at 4 ° C, effective
for 1year (do not freeze).
R-LG02 1 ml 250
R-LG03 2 ml 425
R-LG04 5 ml 720
R-LG05 10 ml 1250
GeneMedi
4.
3
3. No obviouscytotoxicity for most cells, so no need to change the culture medium 72 hours post transfection.
4. Suitable for both adherent and suspension cells, LipoGene can be used for screening for stable expression of cell
lines.
5. For gene silencing, high-efficiency transfections from LipoGene provide a high level of gene knockdown,
achieving convincing results.
6. Easy to use — just need to mix with nucleic acid and add to cultured cells.
Materials
1. LipoGene
2. Expression plasmids in mammanlian cell
More details please visit: https://www.genemedi.net/i/virus-plasmid
3. Cell lines for transfection or viral vectors packaging
PROCEDURE
Overview
Detailed procedures
1. Cell culture: Take 293T cells as an example. The day before transfection (20-24 hours) ~0.4×106 cells (the
specific cell number depends on the cell size and cell growth rate), were inoculated into a six-well plate, so that they
would be 70–90% confluent the next day at the time of transfection.
2. Replace fresh cell culture medium before the following transfection step. The volume of the culture medium is
approximately 2 ml.
GeneMedi
5.
4
Note:
Antibiotics, Glutamine, etc.do no effect on LipoGene transfection. If LipoGene displayed toxicity to the target cells,
it is recommended to remove the antibiotics from the transfection system.
3. Mix the LipoGene liposome transfection reagent gently.
4. Take a sterile centrifuge tube, add 4 μg plasmid to 250 μl of DMEM solution, and mix gently by pipetting.
Note:
If necessary, DMEM can be replaced by other media such as 1640, MEM, F12, etc., which doesn’t effect on the
transfection efficiency of LipoGene. The amounts of plasmids can be appropriately adjusted within the range of 0.1
μg to 4 μg, and the amount of LipoGene is usually 4-8 μl (plasmid volume/LipoGene volume = 1:1 to 1:2). Since the
cell type, culture conditions, transfection parameters, etc. will greatly affect the transfection efficiency, it is
necessary to optimize the plasmid volume/LipoGene volume within the recommended range. For other culture plates
or culture vessels, the amount of each reagent can be converted by referring to the Appendix “LipoGene transfection
instruction table”.
5. Take another sterile centrifuge tube, add 6 μl LipoGene to 250 μl DMEM solution, mix gently with a pipette, and
incubate at room temperature for 5 minutes.
6. Gently mix the DNA solution from steps 4 with LipoGene solution from steps 5 with a pipette.
Note:
Do not vortex or centrifuge.
7. Incubate the LipoGene-DNA mixture for 20 minutes at room temperature. Flocculent deposits may appear, which
is a normal phenomenon and will not affect the transfection efficiency.
8. Add 500 μl of LipoGene-DNA mixture to one well of the six-well plate, either in adherent or suspension cells,
then shake and mix gently in the shape of "8".
9. Note: For adherent cells, as described above, simply add the LipoGene-DNA complex to the cells and incubate for
6 hours before changing the solution. If transfected suspension or semi-suspended cells, it is recommended to use a
flat-angle centrifugation method, after adding the appropriate amount of LipoGene-DNA complex to the cell culture
dish (step 8), seal the sealing film, put it into a flat-angle centrifuge, low speed (200 g) Centrifuge for 1.5 hours, then
put it into the incubator for 6 hours and then change the medium.
10. After 6-12 hours incubation, replace the culture medium with a complete medium and continue to culture.
Note:
LipoGene-DNA mixtures are usually sufficient to produce high transfection efficiency when incubated with cells for
six hours. Most cells were cultured with LipoGene-DNA for up to 72 hours without obvious cytotoxicity. However,
the replacement of fresh medium 6 hours after transfection can improve the transfection efficiency of some cells
which grow very fast. For some easily transfected cells such as HEK-293T cells, whether change of transfection
solution or not depends on cell growth status, and it is not necessary to change the transfection solution to improve
GeneMedi
6.
5
the transfection efficiency.
11.Operations after transfection:
1) For gene expression, transfection efficiency can be detected 24-40 hours later. The expression of GFP or other
fluorescent genes can be observed with fluorescence microscopy.
2) For construction of stable cell lines, appropriate screening drugs such as G418 or puromycin can be added 24
hours post transfection to screen for stable cell lines.
PRECAUTIONS
1. Use high-purity DNA (A260/A280=1.8) to help achieve higher transfection efficiency. For plasmids, high-quality
and endotoxin-free extraction is recommended using the plasmid extraction kit from Qiagen.
2. The state of the cell will greatly affect the efficiency of transfection, so the cells should be in a good state of
growth before transfection.
3. This kit contains no DMEM medium, prepare it by yourself. The other media such as 1640, MEM, alpha-MEM,
F12, DMEM/F12 and M199 can also be used for transfection experiments.
4. LipoGeneTM
liposome transfection reagent can't be vortexed or centrifuged. Just gently shake and mix it when this
reagent has been left standing for a long time.
5. Avoid prolonged exposure to air, which may decrease transfection efficiency.
6. For the health and safety considerations, please perform transfection in a cell culture room that meets the
cleanliness requirements, and wear a lab coat and disposable gloves, a mask, and a sterile cap.
7. LipoGene transfection instruction table:
Culture
vessel
Surface
area per
well
Shared Reagents DNA transfection RNAi transfection
Vol. of plating
medium
Vol. of dilution
medium
DNA LipoGeneTM
RNA LipoGeneTM
96-well 0.3 cm2
100 µl 2 × 25 µl 0.2 µg 0.2-0.4 µl 0.2-0.4 µl 0.2-0.4 µl
48-well 0.8 cm2
350 µl 2 × 37.5 µl 0.5 µg 0.5-1 µl 0.5-1 µl 0.5-1 µl
24-well 2 cm2
500 µl 2 × 50 µl 0.8 µg 0.8-1.6 µl 0.8-1.6 µl 0.8-1.6 µl
12-well 4 cm2
1 ml 2 × 100 µl 1.6 µg 1.6-3.2 µl 1.6-3.2 µl 1.6-3.2 µl
6-well 10 cm2
2 ml 2 × 250 µl 4.0 µg 4-8 µl 4-8 µl 4-8 µl
60mm 20 cm2
4 ml 2 × 0.5 ml 8.0 µg 8-16 µl 8-16 µl 8-16 µl
100mm 60 cm2
12 ml 2 × 1 ml 24 µg 24-48 µl 24-48 µl 24-48 µl
GeneMedi
About GeneMedi
GeneMedi specializesin creating superior antibody, protein, and vector-based
bioproducts, revolutionizing diagnostics and biologics solutions.
At GeneMedi, innovation, product integrity, and scalable solutions form the cornerstone of our mission to advance the field
of diagnostics and biologics. Our portfolio of antibodies, proteins, and vector-derived products is built on a foundation of
unparalleled expertise in the following areas:
Innovative Antigen Design and Robust Assay Development
Our strategic focus on biomarkers and target analysis enables the creation of highly specific antigens
and the development of robust assays, ensuring our products achieve superior performance in clinical
and research settings.
Rapid Protein & Antibody Identification: Our proprietary platforms, TAURUSTM for accelerated
antibody discovery and LIBRATM for AI-driven protein evolution, are designed to identify and optimize
molecules with optimal stability and functionality.
Cutting-Edge AAV & GCT Discoveries: The G-NEXTTM platform is our answer to the industry's
need for innovative AAV vectors, offering improved stability, efficiency, and safety for groundbreaking
gene therapy approaches.
High-Volume Protein & Antibody Manufacturing: Our facilities are equipped to handle large-scale
production of up to 1000L per batch, ensuring high levels of purity and stability through stringent
quality controls.
Advanced Vector Manufacturing Capabilities: In GeneMedi Vector Core (GVC), with a focus on
AAV, Lentivirus, and VLP production up to 200L per batch, we employ sophisticated purification
techniques to guarantee vector efficacy and integrity
Diagnostics: Our diagnostic solutions leverage CLIA, LFA, ELISA and unique POCT platforms for
comprehensive assay validation and clinical sample consistency, setting new standards in diagnostic
accuracy.
Biologics: We specialize in the development of industrial solutions in up/downstream for therapeutic
antibodies, AAV gene therapy, and Cell therapy technologies, ensuring our products and solutions
can improve specificity, potency, and safety in the therapeutic industry.
Streamlined Molecular Discovery with Emphasis on Stability
Scalable Production and Uncompromising Quality
Comprehensive Solutions for Diverse Application Needs
GeneMedi (GM) is dedicated to delivering innovative and scalable biotechnological solutions, driving forward the fields of diagnostics
and therapeutics with confidence and expertise. Contact with GM to reach your reliable industrial partner.
Website: https://www.genemedi.net
Contact Email: support@genemedi.net | sales@genemedi.net
5
トランスフェクション効率。
11. トランスフェクション後の手術
1) 遺伝子発現については、24~40時間後にトランスフェクション効率を検出することができます。GFP などの
蛍光遺伝子の発現を蛍光顕微鏡で観察することができる。
2) 安定した細胞株の構築には、トランスフェクション後 24 時間後に G418 やピューロマイシンなどの適切なス
クリーニング薬を添加して安定した細胞株をスクリーニングすることができます。
注意事項
1. 高純度 DNA(A260/A280=1.8)を使用して、より高いトランスフェクション効率を達成するのに役立ちます。
プラスミドの場合は、キアーゲンからのプラスミド抽出キットを使用して、高品質でエンドトキシンを含まない
抽出をお勧めします。
2. 細胞の状態はトランスフェクションの効率に大きく影響するため、細胞はトランスフェクション前に良好な成
長状態である必要があります。
3. このキットには DMEM 媒体は含まれていません。自分で準備してください。1640、MEM、alpha-
MEM、F12、DMEM/F12、M199 などの他の媒体も、トランスフェクション実験に使用することができる。
4. リポゲネットリポソームトランスフェクション試薬は渦を巻いたり遠心分離したりすることはできません。こ
の試薬が長い間放置されているときは、そっと振って混ぜるだけです。
5. 空気への長時間の曝露を避けるため、トランスフェクション効率が低下する可能性があります。
6. 健康と安全を考慮して、清潔さ要件を満たす細胞培養室でトランスフェクションを行い、ラボコートと使い捨
て手袋、マスク、滅菌キャップを着用してください。
7. リポゲントランスフェクション指示表:
培養容器
井戸あた
りの表面
積
共有試薬 DNA トランスフェ
クション
RNAi 転写
めっき媒体量 希釈媒体容量
DNA;
DNA
脂肪遺伝子 RNA;
RNA;RNA
脂肪遺伝子
96-ウェル 0.3cm2 100 μ l 2 × 25 μ l 0.2 μ
g
0.2~0.4 μ l 0.2~0.4 μ
l
0.2~0.4 μ l
48-ウェル 0.8cm2 350 μ l 2 × 37.5 μ l 0.5 μ
g
0.5~1 μ l 0.5~1 μ l 0.5~1 μ l
24-ウェル 2cm2 500 μ l 2 × 50 μ l 0.8 μ
g
0.8~1.6 μ l 0.8~1.6 μ
l
0.8~1.6 μ l
12-ウェル 4cm2 1 ml 2 × 100 μ l 1.6 μ
g
1.6~3.2 μ l 1.6~3.2 μ
l
1.6~3.2 μ l
6-ウェル 10cm2 2 ml 2 × 250 μ l 4.0 μ
g
4~8 μ l 4~8 μ l 4~8 μ l
60mm 20cm2 4 ml 2 × 0.5ml 8.0 μ
g
8~16 μ l 8~16 μ l 8~16 μ l
100mm 60cm2 12ml 2 × 1ml 24 μ g 24~48 μ l 24~48 μ l 24~48 μ l
About GeneMedi
GeneMedi specializesin creating superior antibody, protein, and vector-based
bioproducts, revolutionizing diagnostics and biologics solutions.
At GeneMedi, innovation, product integrity, and scalable solutions form the cornerstone of our mission to advance the field
of diagnostics and biologics. Our portfolio of antibodies, proteins, and vector-derived products is built on a foundation of
unparalleled expertise in the following areas:
Innovative Antigen Design and Robust Assay Development
Our strategic focus on biomarkers and target analysis enables the creation of highly specific antigens
and the development of robust assays, ensuring our products achieve superior performance in clinical
and research settings.
Rapid Protein & Antibody Identification: Our proprietary platforms, TAURUSTM for accelerated
antibody discovery and LIBRATM for AI-driven protein evolution, are designed to identify and optimize
molecules with optimal stability and functionality.
Cutting-Edge AAV & GCT Discoveries: The G-NEXTTM platform is our answer to the industry's
need for innovative AAV vectors, offering improved stability, efficiency, and safety for groundbreaking
gene therapy approaches.
High-Volume Protein & Antibody Manufacturing: Our facilities are equipped to handle large-scale
production of up to 1000L per batch, ensuring high levels of purity and stability through stringent
quality controls.
Advanced Vector Manufacturing Capabilities: In GeneMedi Vector Core (GVC), with a focus on
AAV, Lentivirus, and VLP production up to 200L per batch, we employ sophisticated purification
techniques to guarantee vector efficacy and integrity
Diagnostics: Our diagnostic solutions leverage CLIA, LFA, ELISA and unique POCT platforms for
comprehensive assay validation and clinical sample consistency, setting new standards in diagnostic
accuracy.
Biologics: We specialize in the development of industrial solutions in up/downstream for therapeutic
antibodies, AAV gene therapy, and Cell therapy technologies, ensuring our products and solutions
can improve specificity, potency, and safety in the therapeutic industry.
Streamlined Molecular Discovery with Emphasis on Stability
Scalable Production and Uncompromising Quality
Comprehensive Solutions for Diverse Application Needs
GeneMedi (GM) is dedicated to delivering innovative and scalable biotechnological solutions, driving forward the fields of diagnostics
and therapeutics with confidence and expertise. Contact with GM to reach your reliable industrial partner.
Website: https://www.genemedi.net
Contact Email: support@genemedi.net | sales@genemedi.net
2
지질체전염시약 프로토콜
포장 내용:병병 1
지방 제품
개
지질전염시약
목록 번호. 패키지 가격 수량/단위 양식 마시기 및 저장 지침
R-LG01 0.5ml 150
병병 1 개. 액체.
4°C 에서 배송되고, 4°C 에서 보관되며, 1 년
간 유효합니다 (동결하지 마십시오).
R-LG02 1ml 250
R-LG03 2ml 425
R-LG04 5ml 720
R-LG05 10ml 1250
저장
lipogene 는 4°C 에서 저장될 수 있습니다. 반복적인 냉동과 해동을 피하세요. 만료일은 제품 라벨에 지정되어 있습
니다.
설명
lipogene liposome transfection 약물은 매우 강력한 양이온 lipofection 약물이며, 플라즈미드 또는 시르나, 그리
고 핵산-단백질 복합물을 배양된 접착성 세포계와 부유성 세포계로 효과적으로 전염시키는 것으로 증명되었다. 연구
자들은 지방유전자 시약을 시르나와 시르나를 기반으로 한 유전자 토너먼트 실험과 유전자 발현 연구에 사용한다.
장점
1. 시르나와 플라스미드 dna 의 공동 전염에 대한 우수한 성능.
2. 혈청의 존재에서 효율적이며, 이는 전염된 후 매체를 바꿀 필요성을 방출한다.
18.
3
3. 대부분의 세포에대해 뚜렷한 세포 독성이 없기 때문에 전염된 72 시간 후에 배양물을 변경할 필요가 없다.
력 있는 결과를 얻는다.
6. 사용하기 쉬운-핵산과 섞어서 배양된 세포에 추가하면 됩니다.
4. 접착세포와 부유세포에 적합한 지방유전자는 세포계의 안정적인 발현을 선별하는 데 사용될 수 있다.
5. 유전자 침묵을 위해서, 지방유전자로부터 효율적으로 전염되는 것은 높은 수준의 유전자 퇴치를 제공하여 설득
재료
1. 지방 유전자
2. 유유세포의 발현 플라스미드
자세한 내용은 https://www.genemedi.net/i/virus-plasmid 를 참조하십시오.
3. 전염되거나 바이러스 매개체를 포장하는 세포계
절차
개요
상세한 절차
1. 세포 배양: 예를 들어 293t 세포를 취하십시오. 전염 전날 (20-24 시간) ~0.4×106 개의 세포(특정 세포수
는 세포의 크기와 세포의 성장속도에 따라 달라진다)를 6 개의 정판에 접종하여 전염 당시 다음날 70-90% 합
류하게 한다.
2. 다음 전염 단계에 앞서 신선한 세포 배양체를 교체하세요. 배양기의 부피는 약 2ml 이다.
19.
4
참고:
항생제, 글루타민 등은지방유전자 전염에 영향을 미치지 않는다. 지질 유전자가 표적 세포에 독성을 나타낸다면, 전염 시스템에
서 항생제를 제거하는 것이 좋다.
3. 지질유전자 지질체 전염 시약을 가볍게 섞으세요.
4. 무균 원심분리기 튜브를 가지고 250μl 의 dmem 용액에 4μg 의 플라즈미드를 첨가한 다음 피펫을 통해 가볍게 섞어라.
참고:
필요하다면 dmem 은 1640, MEM, F12 등과 같은 다른 매체로 대체할 수 있으며, 이는 지방유전자의 전염효율에 영향을 주지 않
는다. 플라스미드의 양은 0.1μg 에서 4μg 의 범위 내에서 적당히 조절할 수 있으며, 지방유전자의 양은 보통 4-8μl(플라스미드 부
피/지방유전자 부피=1:1 에서 1:2)이다. 세포 유형, 배양 조건, 전염 파라미터 등이 전염 효율에 큰 영향을 미치기 때문에, 권장
범위 내에서 플라즈드 부피/지질 유전자 부피를 최적화해야 한다. 다른 배양판이나 배양용기의 경우, 각 시약의 양은 부록 "지방유
전자 전염지시표"를 참조하여 변환할 수 있다.
5. 또 다른 무균 원심분리관, 250μl dmem 용액에 6μl 지방유전자를 첨가한 후 피펠과 가볍게 섞은 후 실온에서 5 분 동안 부화
시킨다.
6. 단계 4 의 dna 용액과 단계 5 의 lipogene 용액을 피펫으로 가볍게 섞으세요.
참고:
소용돌이나 원심분리기는 하지 마세요.
7. 실온에서 지방유전자-dna 혼합물을 20 분 동안 부화시킨다. 응집성 퇴적물이 나타날 수 있는데, 이것은 정상적인 현상이며 전
염의 효율에 영향을 주지 않는다.
8. 유전자-dna 혼합물의 500μl 을 6 개의 정판 중 하나의 정에 첨가하여 접착세포나 부유세포에 넣고 흔들어 "8"의 모양으로 가
볍게 섞으세요.
9. 참고: 위에서 설명한 바와 같이 접착세포의 경우, 세포에 지방유전자-dna 복합체를 첨가하고 6 시간 동안 부화시키기 전에 용
액을 교환하기만 하면 된다. 부유형 또는 반부유형 세포를 전염시킨 경우 평각원심법을 사용하여 세포 배양 접시에 적당량의
lipogene-dna 복합물을 첨가한 후 (단계 8) 밀봉막을 밀봉하고 평각원심분리기에 넣고 저속(200g) 원심분리기에 1.5 시간 넣은
다음 6 시간 동안 인큐베이터에 넣은 다음 배양기를 교환하는 것이 좋습니다.
10. 6-12 시간 부화 후, 배양기를 완전한 배양기로 대체하고 계속 배양한다.
참고:
lipogene-dna 혼합물은 일반적으로 6 시간 동안 세포와 부화할 때 높은 전염 효율을 생성하기에 충분합니다. 대부분의 세포는 지
방유전자-dna 로 최대 72 시간 동안 배양되었는데, 뚜렷한 세포독성이 없었다. 그러나 전염 후 6 시간 후에 신선한 매질을 교체하
면 일부 매우 빠르게 성장하는 세포의 전염 효율을 높일 수 있다. hek-293t 세포와 같은 일부 쉽게 전염되는 세포의 경우, 전염액
의 변경 여부는 세포의 성장 상태에 달려 있으며, 전염액을 변경하여 개선할 필요가 없다
20.
5
전염의 효율성.
11. 전염후 수술:
1) 유전자 발현의 경우, 전염 효율은 24~40 시간 후에 검출될 수 있다. 형광 현미경으로 gfp 또는 다른 형광 유전자의 발현을
관찰할 수 있다.
2) 안정된 세포계를 구축하기 위해 g418 또는 puromycin 과 같은 적절한 선별약을 전염된 24 시간 후에 추가하여 안정된 세포
계를 선별할 수 있다.
주의사항
1. 고순도 dna(A260/A280=1.8)를 사용하여 더 높은 전염 효율을 달성하도록 도와줍니다. 플라즈미드의 경우, 치아겐의 플라즈
미드 추출 키트를 사용하여 고품질의 내독소가 없는 추출을 권장한다.
2. 세포의 상태는 전염의 효율에 큰 영향을 미치기 때문에 전염되기 전에 세포는 양호한 성장 상태에 있어야 한다.
3. 이 키트에는 dmem 매체가 포함되어 있지 않으니 스스로 준비하십시오. 1640, MEM, alpha-MEM, F12, DMEM/F12, m199
와 같은 다른 매질도 전염 실험에 사용할 수 있다.
4. lipogenetm liposome transfection 시약은 소용돌이나 원심분리할 수 없습니다. 이 시약이 오랫동안 머물렀을 때 부드럽게
흔들고 섞으세요.
5. 공기에 장기간 노출되지 않으면 전염 효율이 떨어질 수 있다.
6. 건강과 안전을 고려하여 청결성 요구에 부합하는 세포 배양실에서 전염을 수행하고 실험실 코트와 일회용 장갑, 마스크, 무균
모자를 착용하십시오.
7. lipogene 전염 지시표:
배양 용기
우물당 표면
적
공유 시약 DNA 전염 rnai 전염
볼륨 도금 매질 용량 희석매질
DNA 지방 제품 RNA 지방 제품
96 -정 0.3cm2 100μl 2×25μl 0.2 μg 0.2-0.4μl 0.2-0.4μl 0.2-0.4μl
48 -응 0.8cm2 350 μl 2×37.5μl 0.5μg 0.5-1μl 0.5-1μl 0.5-1μl
24 -응 2cm2 500μl 2×50μl 0.8 μg 0.8-1.6μl 0.8-1.6μl 0.8-1.6μl
12 -응 4 센티미터
2
1ml 2×100μl 1.6μg 1.6-3.2μl 1.6-3.2μl 1.6-3.2μl
6 -응 10cm2 2ml 2×250μl 4.0 μg 4-8μl 4-8μl 4-8μl
60mm 20cm2 4ml 2×0.5ml 8.0 μg 8-16 μl 8-16 μl 8-16 μl
100mm 60cm2 12ml 2×1ml 24 μg 24-48 μl 24-48 μl 24-48 μl
About GeneMedi
GeneMedi specializesin creating superior antibody, protein, and vector-based
bioproducts, revolutionizing diagnostics and biologics solutions.
At GeneMedi, innovation, product integrity, and scalable solutions form the cornerstone of our mission to advance the field
of diagnostics and biologics. Our portfolio of antibodies, proteins, and vector-derived products is built on a foundation of
unparalleled expertise in the following areas:
Innovative Antigen Design and Robust Assay Development
Our strategic focus on biomarkers and target analysis enables the creation of highly specific antigens
and the development of robust assays, ensuring our products achieve superior performance in clinical
and research settings.
Rapid Protein & Antibody Identification: Our proprietary platforms, TAURUSTM for accelerated
antibody discovery and LIBRATM for AI-driven protein evolution, are designed to identify and optimize
molecules with optimal stability and functionality.
Cutting-Edge AAV & GCT Discoveries: The G-NEXTTM platform is our answer to the industry's
need for innovative AAV vectors, offering improved stability, efficiency, and safety for groundbreaking
gene therapy approaches.
High-Volume Protein & Antibody Manufacturing: Our facilities are equipped to handle large-scale
production of up to 1000L per batch, ensuring high levels of purity and stability through stringent
quality controls.
Advanced Vector Manufacturing Capabilities: In GeneMedi Vector Core (GVC), with a focus on
AAV, Lentivirus, and VLP production up to 200L per batch, we employ sophisticated purification
techniques to guarantee vector efficacy and integrity
Diagnostics: Our diagnostic solutions leverage CLIA, LFA, ELISA and unique POCT platforms for
comprehensive assay validation and clinical sample consistency, setting new standards in diagnostic
accuracy.
Biologics: We specialize in the development of industrial solutions in up/downstream for therapeutic
antibodies, AAV gene therapy, and Cell therapy technologies, ensuring our products and solutions
can improve specificity, potency, and safety in the therapeutic industry.
Streamlined Molecular Discovery with Emphasis on Stability
Scalable Production and Uncompromising Quality
Comprehensive Solutions for Diverse Application Needs
GeneMedi (GM) is dedicated to delivering innovative and scalable biotechnological solutions, driving forward the fields of diagnostics
and therapeutics with confidence and expertise. Contact with GM to reach your reliable industrial partner.
Website: https://www.genemedi.net
Contact Email: support@genemedi.net | sales@genemedi.net
2
липогенетм
протокол реагента длятрансфекции липосом
Содержание упаковки: 1 флакон
реагент для трансфекции липогенетма
каталог
номер.
упаковка
упаковки
цена Количество/
единица
форма
форм
ы
рекомендации по поглощению и
хранению
R-LG01 0,5 мл 150
1 флакон. жидкос
ть.
Отправка при 4 ° C, хранение при 4 ° C,
действующая в течение 1 года (не
замораживайте).
R-LG02 1 мл 250
R-LG03 2 мл 425
R-LG04 5 мл 720
R-LG05 10 мл 1250
складское хранение
липоген можно хранить при температуре 4°C. Избегайте повторного замораживания и оттаивания. Дата
истечения срока годности указана на этикетке продукта.
описание
Реагент для трансфекции липогенных липосом представляет собой высокомощный катионный реагент для
липофекции, который, как показано, эффективно трансфектирует плазмиды или сирну, а также комплексы
нуклеиновые кислоты и белки в культивированные адгезивные и суспензионные клеточные линии.
исследователи используют липогенный реагент для экспериментов по нокдауну генов на основе сирны и
шрны, а также для исследований экспрессии генов.
преимущества
1. превосходные характеристики для совместной трансфекции сирны и плазмидной ДНК.
2. эффективно в присутствии сыворотки, что высвобождает необходимость менять среду после трансфекции.
25.
3
3. нет явнойцитотоксичности для большинства клеток, поэтому нет необходимости менять культуральную среду
через 72 часа после трансфекции.
4. Подходит как для адгезивных, так и для суспензионных клеток, липоген может быть использован для скрининга
достигая убедительных результатов.
6.
стабильной экспрессии клеточных линий.
5. для заглушения генов высокоэффективная трансфекция липогена обеспечивает высокий уровень нокдауна генов,
прост в использовании — просто нужно смешивать с нуклеиновой кислотой и добавлять в культивированные
клетки.
Материалы
1. липоген
2. экспрессионные плазмиды в клетках маммана
Более подробная информация посетите: https://www.genemedi.net/i/virus-plasmid.
3. клеточные линии для трансфекции или упаковки вирусных векторов
Процедура
общий обзор
подробные процедуры
1. Культура клеток: возьмите, к примеру, клетки 293 т. за день до трансфекции (20–24 часа) ~0,4 × 106 клеток
(конкретное количество клеток зависит от размера клеток и скорости роста клеток) инокулировали в пластину с
шестью скважинами, так что они будут сливаться на 70–90% на следующий день во время трансфекции.
2. замените свежую клеточную культуру перед следующим этапом трансфекции. объем культуральной среды
составляет около 2 мл.
26.
4
Примечание:
антибиотики, глутамин ит. д. не оказывают никакого влияния на трансфекцию липогена. если липоген
проявляет токсичность для клеток-мишеней, рекомендуется удалить антибиотики из системы трансфекции.
3. аккуратно смешивать реагент для трансфекции липогенных липосом.
4. Возьмите стерильную центрифужную трубку, добавьте 4 мкг плазмиды в 250 мкл раствора dmem и аккуратно
перемешивайте пипеткой.
Примечание:
при необходимости dmem можно заменить другими средами, такими как 1640, MEM, F12 и т. д., что не влияет
на эффективность трансфекции липогена. Количество плазмид можно соответствующим образом
регулировать в диапазоне от 0,1 мкг до 4 мкг, а количество липогена обычно составляет 4-8 мкл (объем
плазмиды/объем липогена = 1:1 до 1:2). поскольку тип клеток, условия культивирования, параметры
трансфекции и т. д. сильно влияют на эффективность трансфекции, необходимо оптимизировать объем
плазмиды/объем липогена в рекомендуемом диапазоне. Для других культуральных пластин или культуральных
сосудов количество каждого реагента можно преобразовать, ссылаясь на добавление «Таблица инструкций по
трансфекции липогена».
5. возьмите другую стерильную центрифужную трубку, добавьте 6 мкл липогена в раствор 250 мкл дмем,
аккуратно перемешивайте с пипеткой и инкубируйте при комнатной температуре в течение 5 минут.
6. аккуратно смешивать раствор ДНК на этапе 4 с раствором липогена на этапе 5 пипеткой.
Примечание:
не вихрь или центрифуга.
7. инкубировать смесь липоген-ДНК в течение 20 минут при комнатной температуре. Возможны флокулентные
отложения, что является нормальным явлением и не влияет на эффективность трансфекции.
8. добавьте 500 мкл смеси липоген-ДНК в одну скважину из шестискважинной пластины, либо в адгезивных или
суспензионных клетках, затем встряхните и аккуратно перемешивайте в форме «8».
9. Примечание: для адгезивных клеток, как описано выше, просто добавьте комплекс липоген-ДНК в клетки и
инкубируйте в течение 6 часов перед заменой раствора. в случае трансфекции суспензионных или
полусуспензионных клеток рекомендуется использовать метод центрифугирования с плоским углом, после
добавления соответствующего количества комплекса липоген-ДНК в тарелку для культивирования клеток (шаг 8),
запечатать герметичную пленку, поместить ее в плоский угловой центрифуга, низкоскоростная (200 г) центрифуга
в течение 1,5 часов, затем поместить ее в инкубатор в течение 6 часов, а затем заменить среду.
10. После 6-12 часов инкубации замените культуральную среду полной средой и продолжите культивировать.
Примечание:
Смеси липоген-ДНК обычно достаточно для выработки высокой эффективности трансфекции при инкубации с
клетками в течение шести часов. большинство клеток культивировали липоген-ДНК в течение до 72 часов без
явной цитотоксичности. однако замена свежей среды через 6 часов после трансфекции может повысить
эффективность трансфекции некоторых клеток, которые растут очень быстро. Для некоторых легко
трансфекцированных клеток, таких как клетки hek-293t, изменение раствора трансфекции зависит от
состояния роста клеток, и нет необходимости менять раствор трансфекции для улучшения.
27.
5
эффективность трансфекции.
11. операциипосле трансфекции:
1) для экспрессии генов эффективность трансфекции может быть обнаружена через 24–40 часов. экспрессия gfp
или других флуоресцентных генов можно наблюдать с помощью флуоресцентной микроскопии.
2) Для построения стабильных клеточных линий можно добавить соответствующие лекарства для скрининга,
такие как g418 или пуромицин, через 24 часа после трансфекции для скрининга на стабильные клеточные
линии.
меры предосторожности
1. используйте ДНК высокой чистоты (A260/A280 = 1,8), чтобы помочь достичь более высокой эффективности
трансфекции. Для плазмид рекомендуется высококачественная и без эндотоксинов экстракция с использованием
комплекта для экстракции плазмид из киагена.
2. состояние клеток сильно повлияет на эффективность трансфекции, поэтому клетки должны быть в хорошем
состоянии роста перед трансфекцией.
3. этот комплект не содержит среды DMEM, приготовьте его самостоятельно. Другие среды, такие как 1640,
MEM, alpha-MEM, F12, DMEM/F12 и m199, также могут быть использованы для экспериментов по трансфекции.
4. Реагент для трансфекции липосом липогенетма не может быть вихрем или центрифугирован. просто аккуратно
встряхните и перемешайте его, когда этот реагент оставлен на стоянии в течение длительного времени.
5. избегайте длительного воздействия воздуха, что может снизить эффективность трансфекции.
6. из соображений здоровья и безопасности, пожалуйста, сделайте трансфекцию в комнате культивирования
клеток, отвечающей требованиям чистоты, и носите лабораторное пальто и одноразовые перчатки, маску и
стерильную кепку.
7. Таблица инструкций по трансфекции липогена:
сосуд для
выращив
ания
площадь
поверхнос
ти на
скважину
общие реагенты трансфекция ДНК Трансфекция рнай
объем
покрытия
среды
объем
разбавляюще
й среды
ДНК липогенетм РНА липогенетм
96-скважин 0,3 см2 100 мкл 2 × 25 мкл 0,2 мкг 0,2-0,4 мкл 0,2-0,4 мкл 0,2-0,4 мкл
48-скважин 0,8 см2 350 мкл 2 × 37,5 мкл 0,5 мкг 0,5-1 мкл 0,5-1 мкл 0,5-1 мкл
24-
квадратный
2 см2 500 мкл 2 × 50 мкл 0,8 мкг 0,8-1,6 мкл 0,8-1,6 мкл 0,8-1,6 мкл
12-скважин 4 см2 1 мл 2 × 100 мкл 1,6 мкг 1,6-3,2 мкл 1,6-3,2 мкл 1,6-3,2 мкл
6-
квадратный
10 см2 2 мл 2 × 250 мкл 4,0 мкг 4-8 мкл 4-8 мкл 4-8 мкл
60 мм 20 см2 4 мл 2 × 0,5 мл 8,0 мкг 8-16 мкл 8-16 мкл 8-16 мкл
100 мм 60 см2 12 мл 2 × 1 мл 24 мкг 24-48 мкл 24-48 мкл 24-48 мкл
About GeneMedi
GeneMedi specializesin creating superior antibody, protein, and vector-based
bioproducts, revolutionizing diagnostics and biologics solutions.
At GeneMedi, innovation, product integrity, and scalable solutions form the cornerstone of our mission to advance the field
of diagnostics and biologics. Our portfolio of antibodies, proteins, and vector-derived products is built on a foundation of
unparalleled expertise in the following areas:
Innovative Antigen Design and Robust Assay Development
Our strategic focus on biomarkers and target analysis enables the creation of highly specific antigens
and the development of robust assays, ensuring our products achieve superior performance in clinical
and research settings.
Rapid Protein & Antibody Identification: Our proprietary platforms, TAURUSTM for accelerated
antibody discovery and LIBRATM for AI-driven protein evolution, are designed to identify and optimize
molecules with optimal stability and functionality.
Cutting-Edge AAV & GCT Discoveries: The G-NEXTTM platform is our answer to the industry's
need for innovative AAV vectors, offering improved stability, efficiency, and safety for groundbreaking
gene therapy approaches.
High-Volume Protein & Antibody Manufacturing: Our facilities are equipped to handle large-scale
production of up to 1000L per batch, ensuring high levels of purity and stability through stringent
quality controls.
Advanced Vector Manufacturing Capabilities: In GeneMedi Vector Core (GVC), with a focus on
AAV, Lentivirus, and VLP production up to 200L per batch, we employ sophisticated purification
techniques to guarantee vector efficacy and integrity
Diagnostics: Our diagnostic solutions leverage CLIA, LFA, ELISA and unique POCT platforms for
comprehensive assay validation and clinical sample consistency, setting new standards in diagnostic
accuracy.
Biologics: We specialize in the development of industrial solutions in up/downstream for therapeutic
antibodies, AAV gene therapy, and Cell therapy technologies, ensuring our products and solutions
can improve specificity, potency, and safety in the therapeutic industry.
Streamlined Molecular Discovery with Emphasis on Stability
Scalable Production and Uncompromising Quality
Comprehensive Solutions for Diverse Application Needs
GeneMedi (GM) is dedicated to delivering innovative and scalable biotechnological solutions, driving forward the fields of diagnostics
and therapeutics with confidence and expertise. Contact with GM to reach your reliable industrial partner.
Website: https://www.genemedi.net
Contact Email: support@genemedi.net | sales@genemedi.net